Clarinex pediatric studies produce an additional six months of market exclusivity for the antihistamine. Schering-Plough submitted an NDA to FDA in December 2002 "seeking clearance to market Clarinex Syrup for children between the ages of six months and two years," the company said. Clarinex is approved for patients 12 and older. Schering's exclusivity for Clarinex now runs until June 21, 2007...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.